

**BBI/SECT/45/2024-25****Date: 13 November 2024**

To,  
The Listing Department,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051

**NSE Symbol: BANKA****Sub: Outcome of Board Meeting dated 13 November 2024.****Ref: Regulation 30 & 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

This is to inform you that the Board of Directors at its Meeting held today, i.e., 13 November 2024, has inter alia, based on the recommendation of the Audit Committee, considered and approved the un-audited standalone and consolidated financial results of the Company for the quarter and half year ended 30 September 2024.

A copy of the aforementioned Financial Results along with the Auditors' Limited Review Report thereon pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") is enclosed herewith.

We are also arranging to upload the aforesaid Financial Results on the Company's Website at [www.bankabio.com](http://www.bankabio.com) and shall publish the Financial Results in the newspapers, in the format prescribed under Regulation 47 of the SEBI Listing Regulations.

The meeting commenced at 03:30 PM and concluded at 05:50 PM.

We request you to kindly take note of the same in your record.

Thank you,

**For Banka BioLoo Limited****Nitika Lakhotia**  
**Company Secretary & Compliance Officer***Encl: As above*



**Independent Auditor's Review Report on the Unaudited Standalone Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**To The Board of Directors of BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter and half year ended September 30, 2024 and the Standalone Unaudited Balance Sheet and Cash Flow Statement as at September 30, 2024 (the "statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 (the Circular).
2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contain any material misstatement.





**B.D. SABOO & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

---

5. The financial results shown under columns "Quarter ended 30.09.2023 -Unaudited," "Half year ended 30.09.2023 -Unaudited" and "Year ended 31.03.2024 -Audited" contained in the statement have been reviewed/audited by PRSV and Co LLP, the predecessor auditor, on which they have issued an unmodified conclusion/opinion.

**For B.D. Saboo and Associates**

Chartered Accountants

Firm Registration No: 003505s

**Shyam Sunder Modani**

Partner

Membership No: 213530



Place: Hyderabad

Date: 13-11-2024

UDIN: 24213530BKAKLQ9967.

**Banka BioLoo Limited**  
Statement of STANDALONE assets and liabilities as at 30.09.2024

Rs In Lakhs

Particulars	Unaudited	Audited
	As at 30.09.2024	As at 31.03.2024
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment (PPE)	908.14	964.01
Capital work in progress	734.93	650.90
Right-of-use assets	63.85	91.53
Intangible assets	9.87	10.69
Financial assets		
Investments	100.50	533.76
Other financial assets	464.57	542.30
<b>Total non-current assets</b>	<b>2,281.86</b>	<b>2,793.19</b>
<b>Current assets</b>		
Inventories	660.66	535.36
Financial assets		
Trade receivables	2,470.98	1,958.84
Cash and cash equivalents	2.15	26.93
Other bank balances	492.97	216.58
Loans	11.28	275.23
Other financial assets	846.87	984.79
Income tax assets	115.31	125.48
Other current assets	211.04	160.65
<b>Total current assets</b>	<b>4,811.26</b>	<b>4,283.87</b>
<b>Total assets</b>	<b>7,093.13</b>	<b>7,077.06</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,084.66	1,084.66
Other equity	2,445.08	3,035.06
<b>Total equity</b>	<b>3,529.74</b>	<b>4,119.72</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	480.18	702.23
Lease liabilities	17.71	47.59
Provisions	75.99	56.50
Deferred tax liabilities (Net)	23.08	32.83
<b>Total Non-current liabilities</b>	<b>596.96</b>	<b>839.15</b>
<b>Current liabilities</b>		
Financial Liabilities		
Short-term borrowings	1,819.48	1,208.21
Trade payables		
Total outstanding dues of micro and small enterprise	29.82	36.72
Total outstanding dues of creditors other than micro and small enterprise	259.68	251.32
Short- term lease liabilities	63.80	65.18
Other financial liabilities	21.63	25.14
Other current liabilities	765.18	526.58
Provisions	6.84	5.04
<b>Total Current liabilities</b>	<b>2,966.44</b>	<b>2,118.19</b>
<b>Total Equity &amp; Liabilities</b>	<b>7,093.13</b>	<b>7,077.06</b>

For & on behalf of board of directors

Place: Hyderabad  
Date: 13.11.2024

Vishal Murarka  
CEO & Executive Director  
DIN: 06729485

Banka BioLoo Limited

Unaudited STANDALONE statement of financial results for the quarter and half year ended 30.09.2024

Rs In Lakhs

Sl. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
<b>1</b>	<b>Income</b>						
	Revenue from Operations	1434.01	1238.75	1055.42	2672.77	1866.25	4997.45
	Other income	8.30	18.84	16.97	27.14	38.15	76.65
	<b>Total Income</b>	<b>1442.32</b>	<b>1257.59</b>	<b>1072.39</b>	<b>2699.91</b>	<b>1904.39</b>	<b>5074.11</b>
<b>2</b>	<b>Expenses</b>						
	Cost of materials consumed	355.24	218.36	189.48	573.59	482.14	1175.13
	Changes in inventories of finished goods & work- in-progress	14.09	69.68	(11.02)	83.77	32.77	546.85
	Employee benefits expense	691.53	701.65	544.54	1393.18	1058.97	2358.10
	Finance costs	61.84	67.87	50.99	129.70	91.97	200.58
	Depreciation and amortisation expense	44.83	45.11	42.27	89.94	84.13	172.36
	Other expenses	219.95	104.09	153.15	324.04	236.95	579.68
	<b>Total expenses</b>	<b>1387.48</b>	<b>1206.75</b>	<b>969.41</b>	<b>2594.22</b>	<b>1986.91</b>	<b>5032.69</b>
<b>3</b>	<b>Profit before exceptional items and tax</b>	<b>54.84</b>	<b>50.84</b>	<b>102.98</b>	<b>105.68</b>	<b>(82.52)</b>	<b>41.42</b>
<b>4</b>	<b>Exceptional items</b>	712.27	-	-	712.27	-	-
<b>5</b>	<b>Profit/(loss) before tax.</b>	<b>(657.43)</b>	<b>50.84</b>	<b>102.98</b>	<b>(606.58)</b>	<b>(82.52)</b>	<b>41.42</b>
<b>6</b>	<b>Tax expense</b>						
	(1) Current tax	6.41	7.04	2.75	13.46	2.75	-
	(2) Taxes for earlier years	-	-	-	-	-	1.93
	(3) MAT Credit	-	-	-	-	-	-
	(4) Deferred tax	(11.25)	1.51	(5.44)	(9.75)	(7.19)	6.84
	<b>Total Tax expense</b>	<b>(4.84)</b>	<b>8.55</b>	<b>(2.69)</b>	<b>3.71</b>	<b>(4.44)</b>	<b>8.77</b>
<b>7</b>	<b>Profit after tax</b>	<b>(652.58)</b>	<b>42.29</b>	<b>105.67</b>	<b>(610.29)</b>	<b>(78.08)</b>	<b>32.65</b>
	<b>Other comprehensive income</b>						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations	-	-	-	-	-	20.85
	Income tax effect on items that will not be reclassified	-	-	-	-	-	(5.25)
<b>8</b>	<b>Other comprehensive income for the year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>15.60</b>
<b>9</b>	<b>Total comprehensive income for the year</b>	<b>(652.58)</b>	<b>42.29</b>	<b>105.67</b>	<b>(610.29)</b>	<b>(78.08)</b>	<b>48.25</b>
<b>10</b>	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1084.66	1084.66	1084.66	1084.66
<b>11</b>	<b>Earnings per share</b>						
	Basic Earnings per share (in Rs.)	(6.02)	0.39	0.97	(5.63)	(0.72)	0.30
	Diluted Earnings per share (in Rs.)	(6.02)	0.38	0.97	(5.63)	(0.72)	0.30
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

For & on behalf of board of directors

Place: Hyderabad

Date: 13.11.2024

Vishal Murarka

CEO & Executive Director

DIN: 06729485

**Banka BioLoo Limited****Standalone statement of cash flows for the period ending 30.09.2024****Rs In Lakhs**

<b>Particulars</b>	<b>Half Year Ended 30.09.2024</b>	<b>Half Year Ended 30.09.2023</b>
<b>A. Cash flows from/(used in) operating activities</b>		
Net profit before tax	(606.58)	(82.52)
Adjustments for:		
Depreciation and amortisation expense	89.94	84.13
Finance cost	124.13	83.20
Interest on lease rentals	5.57	8.77
Employee stock option-discount forming part of employee benefits expense	20.31	-
Profit on sale of PPE	(0.40)	-
Provison for investments in subsidiary & loan	712.27	-
Interest income	(19.51)	(38.15)
<b>Operating profit before working capital changes</b>	<b>325.73</b>	<b>55.42</b>
<i>Changes in operating assets and liabilities</i>		
(Increase)/decrease in inventories	(125.30)	(50.82)
(Increase)/decrease in trade receivables	(512.14)	188.98
Increase/(decrease) in trade payables	1.47	(10.18)
(Increase)/decrease in other financial assets	29.27	162.17
(Increase)/decrease in non financial assets	(10.28)	0.21
Increase/(decrease) in other financial liabilities	(3.51)	(26.78)
Increase/(decrease) in non financial liabilities	238.60	(21.15)
Increase/(decrease) provisions	21.28	10.00
<b>Cash (used in)/from operating activities</b>	<b>(34.87)</b>	<b>307.86</b>
Tax paid	43.40	43.63
<b>Net cash (used in)/ from operating activities</b>	<b>(78.27)</b>	<b>264.23</b>
<b>B. Cash flow from/(used in) investing activity</b>		
Purchase of PPE, Investment property and Intangible assets	(91.20)	(304.08)
Sale of PPE, Investment property and Intangible assets	2.00	-
(Increase)/decrease Investment in associates	-	2.00
(Increase)/decrease in loans to subsidiaries	(4.73)	(32.39)
(Increase)/decrease in Deposits	(90.02)	(199.15)
Interest received	9.18	38.15
<b>Net cash (used in)/from investing activities</b>	<b>(174.77)</b>	<b>(495.47)</b>
<b>C. Cash flows from/(used in) financing activities</b>		
(Repayment)/proceeds of borrowings	389.22	292.65
Payment of lease liabilities	(36.83)	(35.08)
Interest paid	(124.13)	(83.20)
<b>Net cash (used in)/from financing activities</b>	<b>228.26</b>	<b>174.38</b>
<b>Net increase /(decrease) in cash and cash equivalents</b>	<b>(24.78)</b>	<b>(56.86)</b>
Add: Cash and cash equivalents at the beginning of the year	26.93	82.67
<b>Cash and cash equivalents at the end of the year</b>	<b>2.15</b>	<b>25.81</b>

For &amp; on behalf of board of directors

Place: Hyderabad

Date: 13.11.2024

Vishal Murarka

CEO &amp; Executive Director

DIN: 06729485

**Notes:**

1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 November 2024.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter and half year ended 30 September 2024 have been prepared following the same accounting policies as those followed for the annual financial statements for the year ended 31 March 2024.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
7. Enzotech Solutions Private Limited, a wholly-owned subsidiary of the Company, has approved the filing of an application under Section 6 read with Section 10 of the Insolvency and Bankruptcy Code, 2016, to initiate a voluntary Corporate Insolvency Resolution Process (CIRP) before the Hon'ble National Company Law Tribunal (NCLT), Chennai Bench. Considering this development, while preparing the standalone financial statements in accordance with Ind As 36 management of Banka BioLoo Limited has evaluated the recoverability of assets (Investment & Loans to Subsidiary) and one-time provision classified as an exceptional item amounting to ₹712.27 lakhs has been recognized, aligning with the principles outlined in Ind AS 36. These provisions will be continuously reviewed and updated based on further developments in the CIRP proceedings and any subsequent financial implications.
8. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For **Banka Bioloo Limited**

**Vishal Murarka**  
CEO & Executive Director  
DIN: 06729485

Place: Hyderabad  
Date: 13 November 2024



Independent Auditor's Review Report on Review of Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To  
Board of Directors of **BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of Consolidated unaudited financial results of **BANKA BIOLOO LIMITED** ("the Parent") its Subsidiaries (the Parent and Subsidiaries together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associate for the quarter ended September 30, 2024 and for the period from April 1, 2024 to September 30, 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the parent's management and approved by the parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended to the extent applicable.

4. The Statement includes the results of the following entities.

**Holding/Parent Company**

BANKA BIOLOO LIMITED

**Wholly Owned Subsidiary**

ENZOTECH SOLUTIONS PRIVATE LIMITED

**Subsidiary**

MEGALITER VARUNAA PRIVATE LIMITED

**Associate**

SAI BANKA SPV PRIVATE LIMITED (with a share of 50% to the holding company)








Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

**Other Matter**

We did not review the interim financial information of two subsidiary included in the unaudited consolidated financial results, which have not been reviewed by their auditor, whose interim financial information reflect total assets of Rs.1121.49 lacs, total revenues of Rs. 56.34 Lacs and Rs.112.44 Lacs, total net loss after tax of Rs.629.98 Lacs and Rs.644.77 Lacs and total comprehensive loss of Rs.629.98 Lacs and Rs.644.77 Lacs for the quarter ended September 30, 2024, and for the period from April 1, 2024, to September 30, 2024, respectively and cash flows (net) of Rs. (1.45) Lacs for the period from April 1, 2024, to September 30, 2024 as the consolidated unaudited financial results. The statement also includes financial results of one associate as mentioned above, whose share of net profit after tax of Rs. 0.43 Lacs and Rs.1.16 Lacs total comprehensive income of Rs. 0.43 Lacs and Rs.1.16 Lacs for the quarter ended September 30, 2024 and for the period from April 1, 2024 to September 30, 2024, respectively, as considered in the unaudited consolidated financial results, based on their interim financial results which have not been reviewed by the auditors and which has been furnished to us by the Management. According to the information and explanations given to us by the management, these unaudited interim standalone financial results are not material to the group.

5. The financial results shown under columns "Quarter ended 30.09.2023 -Unaudited", "Half year ended 30.09.2023 -Unaudited" and "Year ended 31.03.2024 -Audited" contained in the statement have been reviewed/audited by PRSV and Co LLP, the predecessor auditor, on which they have issued an unmodified conclusion/opinion.

**For B.D. Saboo and Associates**  
Chartered Accountants  
Firm Registration No. 003505s

  
**Shyam Sunder Modani**  
Partner  
Membership No. 213530



Place: Hyderabad  
Date: 13-11-2024

UDIN: 24213530BKAKLR4051.

Banka BioLoo Limited  
Statement of CONSOLIDATED assets and liabilities as at 30.09.2024

Rs. In Lakhs

Particulars	Unaudited As at 30.09.2024	Audited As at 31.03.2024
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	1315.26	1404.88
Capital work in progress	929.51	650.90
Right-to-use asset	63.85	91.53
Intangible assets	9.87	10.69
Goodwill on consolidation	-	31.51
Financial assets		
Investments	2.71	1.54
Other financial assets	539.48	617.21
<b>Total non-current assets</b>	<b>2860.67</b>	<b>2808.26</b>
<b>Current assets</b>		
Inventories	658.76	826.46
Financial assets		
Trade receivables	2469.09	2296.48
Cash and cash equivalents	4.82	31.06
Other bank balances	514.44	238.05
Loans	11.28	12.64
Other financial assets	846.87	1125.68
Income tax assets	115.31	125.48
Other current assets	351.13	278.15
<b>Total current assets</b>	<b>4971.72</b>	<b>4934.01</b>
<b>Total assets</b>	<b>7832.39</b>	<b>7742.27</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1084.66	1084.66
Other equity	2324.12	2887.33
<b>Equity attributable to shareholders of the company</b>	<b>3408.78</b>	<b>3971.99</b>
<b>Non-controlling interests</b>	3.94	4.18
<b>Total equity</b>	<b>3412.72</b>	<b>3976.18</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	1024.71	1091.10
Lease liabilities	17.71	47.59
Provisions	75.99	56.50
Deferred tax liabilities (Net)	25.88	35.76
<b>Total Non-current liabilities</b>	<b>1144.29</b>	<b>1230.96</b>
<b>Current liabilities</b>		
Financial Liabilities		
Short-term borrowings	2132.37	1387.42
Trade payables		
Total outstanding dues of micro and small enterprises	91.25	98.15
Total outstanding dues of creditors other than micro and small enterprises	306.61	294.70
Lease liabilities	63.80	65.18
Other financial liabilities	148.08	150.52
Other current liabilities	526.45	534.13
Provisions	6.84	5.04
<b>Total Current liabilities</b>	<b>3275.39</b>	<b>2535.14</b>
<b>Total Equity &amp; Liabilities</b>	<b>7832.39</b>	<b>7742.27</b>

For & on behalf of board of directors

Place: Hyderabad  
Date: 13.11.2024

Vishal Murarka  
CEO & Executive Director  
DIN: 06729485

Banka BioLoo Limited

Unaudited CONSOLIDATED statement of financial results for the quarter and half year ended 30.09.2024

Rs. In Lakhs

S. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2023
<b>1</b>	<b>Income</b>						
	Revenue from Operations	1241.14	1288.55	1145.08	2529.69	1972.63	4999.62
	Other income	8.30	11.33	9.16	19.63	26.44	49.45
	<b>Total Income</b>	<b>1249.44</b>	<b>1299.88</b>	<b>1154.24</b>	<b>2549.32</b>	<b>1999.07</b>	<b>5,049.06</b>
<b>2</b>	<b>Expenses</b>						
	Cost of materials consumed	348.28	237.68	211.50	585.96	504.57	1077.49
	Changes in inventories of finished goods & work-in-progress	100.39	69.68	(10.44)	170.07	47.32	546.42
	Employee benefits expense	691.53	701.65	555.68	1393.18	1085.36	2393.12
	Finance costs	85.07	87.46	68.01	172.52	118.81	247.45
	Depreciation and amortisation expense	61.84	61.84	55.03	123.69	100.97	218.87
	Other expenses	549.01	104.74	158.95	653.75	257.69	619.95
	<b>Total expenses</b>	<b>1836.12</b>	<b>1263.05</b>	<b>1038.73</b>	<b>3099.17</b>	<b>2114.71</b>	<b>5,103.29</b>
<b>3</b>	Share of profit/(loss) of Associates	0.43	0.73	0.53	1.16	1.37	(2.10)
<b>4</b>	<b>Profit/(loss) before tax exceptional items</b>	<b>(586.25)</b>	<b>37.57</b>	<b>116.04</b>	<b>(548.68)</b>	<b>(114.26)</b>	<b>(56.33)</b>
<b>5</b>	<b>Exceptional items</b>	<b>31.51</b>	<b>-</b>	<b>-</b>	<b>31.51</b>	<b>-</b>	<b>-</b>
<b>6</b>	<b>Profit/(loss) before tax</b>	<b>(617.77)</b>	<b>37.57</b>	<b>116.04</b>	<b>(580.20)</b>	<b>(114.26)</b>	<b>(56.33)</b>
<b>7</b>	<b>Tax expense</b>						
	(1) Current tax	6.41	7.04	(2.13)	13.46	2.75	-
	(2) Taxes for earlier years	-	-	-	-	-	1.93
	(3) MAT Credit	-	-	-	-	-	-
	(4) Deferred tax	(11.20)	1.31	(3.77)	(9.88)	(5.55)	8.85
	<b>Total Tax expense</b>	<b>(4.78)</b>	<b>8.36</b>	<b>(5.90)</b>	<b>3.57</b>	<b>(2.80)</b>	<b>10.78</b>
<b>8</b>	<b>Profit after tax</b>	<b>(612.98)</b>	<b>29.21</b>	<b>121.94</b>	<b>(583.77)</b>	<b>(111.46)</b>	<b>(67.11)</b>
	<b>Other comprehensive income</b>						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations	-	-	-	-	-	20.85
	Income tax effect on items that will not be reclassified	-	-	-	-	-	(5.25)
<b>9</b>	<b>Other comprehensive income for the year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>15.60</b>
<b>10</b>	<b>Total comprehensive income for the year</b>	<b>(612.98)</b>	<b>29.21</b>	<b>121.94</b>	<b>(583.77)</b>	<b>(111.46)</b>	<b>(51.50)</b>
	<b>Attributable to</b>						
	Shareholders of the Company	(612.83)	29.31	121.94	(583.52)	(111.60)	(49.64)
	Non controlling interest	(0.16)	(0.09)	0.14	(0.25)	0.14	(1.86)
<b>11</b>	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1084.66	1084.66	1084.66	1,084.66
<b>12</b>	<b>Earnings per share</b>						
	Basic Earnings per share (in Rs.)	(5.65)	0.27	1.12	(5.38)	(1.03)	(0.6)
	Diluted Earnings per share (in Rs.)	(5.65)	0.27	1.12	(5.38)	(1.03)	(0.6)
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

For & on behalf of board of directors

Place: Hyderabad  
Date: 13.11.2024

Vishal Murarka  
CEO & Executive Director  
DIN: 06729485

## Banka BioLoo Limited

## CONSOLIDATED statement of cash flows for the period ending 30.09.2024

Rs in Lakhs

Particulars	Half Year Ended 30.09.2024	Half Year Ended 30.09.2023
<b>A. Cash flows from/(used in) operating activities</b>		
Net profit before tax	(580.20)	(114.26)
Adjustments for:	-	-
Depreciation and amortisation expense	123.69	100.97
Finance cost	166.95	110.04
Interest on Lease Rentals	5.57	8.77
Employee stock option-discount forming part of employee benefits expense	20.31	-
Profit on sale of PPE	(0.40)	-
Provision for Goodwill	31.51	-
Interest income	(11.99)	(26.44)
<b>Operating profit before working capital changes</b>	<b>(244.56)</b>	<b>79.06</b>
<i>Changes in operating assets and liabilities</i>		
(Increase)/decrease in inventories	167.70	(21.07)
(Increase)/decrease in trade receivables	(172.61)	(1,073.15)
Increase/(decrease) in trade payables	5.01	(12.61)
(Increase)/decrease in other financial assets	398.45	154.72
(Increase)/decrease in non financial assets	(72.80)	923.05
Increase/(decrease) in other financial liabilities	(2.44)	(29.29)
Increase/(decrease) in non financial liabilities	(7.68)	60.40
Increase/(decrease) provisions	21.28	10.00
<b>Cash (used in)/from operating activities</b>	<b>92.35</b>	<b>91.11</b>
Tax paid	45.20	43.91
<b>Net cash (used in)/ from operating activities</b>	<b>47.15</b>	<b>47.20</b>
<b>B. Cash flow from/(used in) investing activity</b>		
Purchase of PPE, Investment property and Intangible assets	(285.78)	(366.78)
Sale of PPE, Investment property and Intangible assets	2.00	-
(Increase)/decrease Investment in associates	(1.16)	0.63
(Increase)/decrease in loans to subsidiaries	1.36	-
(Increase)/decrease in Deposits	(276.39)	(199.15)
Interest received	11.82	26.44
<b>Net cash (used in)/from investing activities</b>	<b>(548.16)</b>	<b>(538.85)</b>
<b>C. Cash flows from/(used in) financing activities</b>		
Proceeds from issue of Share Capital	-	5.26
(Repayment)/proceeds of borrowings	678.56	576.96
Payment of lease liabilities	(36.83)	(35.08)
Interest paid	(166.95)	(110.04)
<b>Net cash (used in)/from financing activities</b>	<b>474.78</b>	<b>437.10</b>
<b>Net increase /(decrease) in cash and cash equivalents</b>	<b>(26.23)</b>	<b>(54.55)</b>
Add: Cash and cash equivalents at the beginning of the period.	31.06	84.07
<b>Cash and cash equivalents at the end of the year</b>	<b>4.82</b>	<b>29.52</b>

For &amp; on behalf of board of directors

Place: Hyderabad

Date: 13.11.2024

Vishal Murarka

CEO &amp; Executive Director

DIN: 06729485

**Notes:**

1. The above statement of unaudited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 November 2024.
2. The Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards (“INDAS”) prescribed under section 133 of the Companies Act 2013 (“the Act”) read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Megaliter Varunaa Pvt Ltd	Subsidiary
Sai Banka SPV Pvt Ltd	Associate with 50% share to the Company

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Consolidated Financial Results for the quarter & half year ended 30 September 2024 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31 March 2024.
6. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
7. Enzotech Solutions Private Limited, a wholly-owned subsidiary of the Company, has approved the filing of an application under Section 6 read with Section 10 of the Insolvency and Bankruptcy Code, 2016, to initiate a voluntary Corporate Insolvency Resolution Process (CIRP) before the Hon’ble National Company Law Tribunal (NCLT), Chennai Bench. Considering this development, management has evaluated the recoverability of assets and the necessity for provisions in the consolidated financial statements in accordance with Ind AS 36. Consequently, an amount of Rs: -31.51 Lakhs provision been recognized towards impairment of goodwill, aligning with the principles outlined in Ind AS 36. These provisions will be continuously reviewed and updated based on further developments in the CIRP proceedings and any subsequent financial implications.
8. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For **Banka Bioloo Limited**

**Vishal Murarka**  
CEO & Executive Director  
DIN: 06729485

Place: Hyderabad  
Date: 13 November 2024